Galunisertib plus capecitabine
PreclinicalSmall molecule
Galunisertib plus capecitabine is one of 7 small molecule programs targeting Colorectal Cancer Metastatic. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Colorectal Cancer Metastatic
#DrugCompanyPhaseTrials
1FOLFIRI
AmgenPhase 3
SHR-A1904
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 2
Balstilimab
AAgenus Inc.
Phase 2
Botensilimab
AAgenus Inc.
Phase 2
Folfiri+cetuximab
NNational Cancer Institute, Naples
Phase 3
Agent-797
MMiNK Therapeutics
Phase 2
Galunisertib plus capecitabine
TThe Netherlands Cancer Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TThe Netherlands Cancer Institute